Kathleen D. Scott has served as our Chief Financial Officer since February 2022. Ms. Scott previously served as the Chief Financial Officer of various life science companies, including Neurana Pharmaceuticals, Inc. (from 2017 to March 2022), Recros Medica, Inc. (from 2014 to April 2021), Adigica Health, Inc. (from 2016 to March 2021), Clarify Medical, Inc. (from 2014 to 2016), Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (in 2016), MDRejuvena, Inc. (from 2014 to 2016) and BioSurplus, Inc. (from 2010 to 2014). Ms. Scott also previously served as a partner at RA Capital Advisors LLC, a San Diego private investment bank providing financial advisory services. She spent over 15 years with RA Capital Advisors, completing mergers, acquisitions, divestitures and restructurings for a broad range of corporate clients. Ms. Scott started her career as an auditor in Arthur Andersen’s San Diego office, focusing on both public and private clients. Ms. Scott serves on the boards of directors of Dermata Therapeutics, Inc. (Nasdaq: DRMA), where she has served since August 2021, NKGen Biotech, Inc. (Nasdaq: NKGN), where she has served since September 2023, and the YMCA of San Diego County, and previously served as a member of the board of Conatus Pharmaceuticals Inc. from November 2019 to May 2020. Ms. Scott holds a bachelor’s degree in economics/business from the University of California, Los Angeles and is a CPA and CFA charter holder.
What is Kathleen D. Scott's net worth?
The estimated net worth of Kathleen D. Scott is at least $61,813.01 as of October 16th, 2024. Ms. Scott owns 4,949 shares of ARS Pharmaceuticals stock worth more than $61,813 as of March 29th. This net worth evaluation does not reflect any other investments that Ms. Scott may own. Learn More about Kathleen D. Scott's net worth.
How do I contact Kathleen D. Scott?
The corporate mailing address for Ms. Scott and other ARS Pharmaceuticals executives is 500 Fairview Ave N Suite 600, Seattle WA, 98109. ARS Pharmaceuticals can also be reached via phone at 206-456-2900 and via email at ir@silverbacktx.com. Learn More on Kathleen D. Scott's contact information.
Has Kathleen D. Scott been buying or selling shares of ARS Pharmaceuticals?
Kathleen D. Scott has not been actively trading shares of ARS Pharmaceuticals over the course of the past ninety days. Most recently, Kathleen D. Scott sold 12,500 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $16.00, for a transaction totalling $200,000.00. Following the completion of the sale, the chief financial officer now directly owns 4,949 shares of the company's stock, valued at $79,184. Learn More on Kathleen D. Scott's trading history.
Who are ARS Pharmaceuticals' active insiders?
Are insiders buying or selling shares of ARS Pharmaceuticals?
In the last twelve months, insiders at the sold shares 37 times. They sold a total of 2,961,053 shares worth more than $39,496,274.18. The most recent insider tranaction occured on March, 20th when insider Eric Karas sold 10,000 shares worth more than $140,000.00. Insiders at ARS Pharmaceuticals own 40.1% of the company.
Learn More about insider trades at ARS Pharmaceuticals. Information on this page was last updated on 3/20/2025.
